药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
Difenoxin
Iratumumab
The risk or severity of adverse effects can be increased when Iratumumab is combined with Polatuzumab vedotin.
Difenoxin
AMG 108
The risk or severity of adverse effects can be increased when AMG 108 is combined with Polatuzumab vedotin.
Difenoxin
Otelixizumab
The risk or severity of adverse effects can be increased when Otelixizumab is combined with Polatuzumab vedotin.
Difenoxin
Briakinumab
The risk or severity of adverse effects can be increased when Briakinumab is combined with Polatuzumab vedotin.
Difenoxin
NAV 1800
The risk or severity of adverse effects can be increased when NAV 1800 is combined with Polatuzumab vedotin.
Difenoxin
XTL-001
The risk or severity of adverse effects can be increased when XTL-001 is combined with Polatuzumab vedotin.
Difenoxin
Obiltoxaximab
The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Polatuzumab vedotin.
Difenoxin
Girentuximab
The risk or severity of adverse effects can be increased when Girentuximab is combined with Polatuzumab vedotin.
Difenoxin
Rozrolimupab
The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Polatuzumab vedotin.
Difenoxin
CR002
The risk or severity of adverse effects can be increased when CR002 is combined with Polatuzumab vedotin.
Difenoxin
Bavituximab
The risk or severity of adverse effects can be increased when Bavituximab is combined with Polatuzumab vedotin.
Difenoxin
Fontolizumab
The risk or severity of adverse effects can be increased when Fontolizumab is combined with Polatuzumab vedotin.
Difenoxin
Matuzumab
The risk or severity of adverse effects can be increased when Matuzumab is combined with Polatuzumab vedotin.
Difenoxin
Labetuzumab
The risk or severity of adverse effects can be increased when Labetuzumab is combined with Polatuzumab vedotin.
Difenoxin
Adecatumumab
The risk or severity of adverse effects can be increased when Adecatumumab is combined with Polatuzumab vedotin.
Difenoxin
IGN311
The risk or severity of adverse effects can be increased when IGN311 is combined with Polatuzumab vedotin.
Difenoxin
Oregovomab
The risk or severity of adverse effects can be increased when Oregovomab is combined with Polatuzumab vedotin.
Difenoxin
Bectumomab
The risk or severity of adverse effects can be increased when Bectumomab is combined with Polatuzumab vedotin.
Difenoxin
Epratuzumab
The risk or severity of adverse effects can be increased when Epratuzumab is combined with Polatuzumab vedotin.
Difenoxin
Pexelizumab
The risk or severity of adverse effects can be increased when Pexelizumab is combined with Polatuzumab vedotin.